Specific Biologics Raises $35M Series A for ALS Gene-Editing Therapy

Hatteras leads an oversubscribed round that funds a first Phase I/II cohort testing Dualase in C9ORF72-associated ALS.

Specific Biologics, a venture-backed biotechnology company pioneering precision gene-editing therapies for serious genetic diseases, has closed an oversubscribed US$35 million Series A financing led by Hatteras Venture Partners, according to a company announcement issued from Toronto via CNW on Nov. 2. The company did not disclose a valuation.


Foundational investors Lumira Ventures and adMare BioInnovations participated in the round. They were joined by new investors Genesys Capital, the Business Development Bank of Canada's Life Sciences Venture Fund, DeepWork Capital and Seido Capital. The release did not state a cumulative funding total.


Dualase and the ALS Target


The company's proprietary Dualase platform is designed to remove disease-causing DNA repeat expansions while preserving normal sequences. Repeat expansions are linked to more than 40 genetic disorders, and the company says it has shown preclinical editing in several neuromuscular repeat expansions. The editor is compact enough to fit in a single adeno-associated virus (AAV) for direct delivery to the central nervous system, and it can also be delivered as mRNA in lipid nanoparticles.


The first target is ALS tied to C9ORF72 repeat expansions, the most common known inherited genetic cause of the disease, which is also associated with frontotemporal dementia. ALS is a progressive and ultimately fatal neurodegenerative disease with no approved therapies. In patient-derived ALS cell models, the company reports that Dualase achieved nearly complete collapse of the pathogenic C9ORF72 repeat expansion, and that in disease-relevant animal models it corrected downstream disease hallmarks with no detectable off-target effects.


Where the Money Goes


Proceeds will carry the lead Dualase candidate through initial clinical biomarker proof-of-concept in the first cohort of an adaptive Phase I/II trial in patients with C9ORF72-associated ALS. The announcement did not give dates for trial start or readout.


Chief Executive Officer Brent Stead called the financing "a defining step toward our goal of bringing a potentially transformative medicine" to people living with ALS.


The Investor View


Ben Scruggs, a partner at Hatteras Venture Partners, said gene editing could transform the treatment of genetic diseases but that challenges in precision, specificity and delivery must first be solved. He said "Specific Biologics has developed a highly differentiated technology with significant therapeutic and commercial potential," pointing to its preclinical evidence.


Nikhil Thatte, a partner at Lumira Ventures, described the chance to generate early clinical proof-of-concept in ALS patients as "an important inflection point for the company." Board Chair Paul Hastings said the technology could open the door to therapies for genetic conditions "that have historically been beyond reach."


Why It Matters


The round is sized to answer one question: whether Dualase's preclinical results translate into a measurable biomarker signal in people. By tying the capital to the first cohort of a Phase I/II study rather than a broad pipeline build-out, the company and its investors have set a clear, near-term test for the platform.


The choice of C9ORF72 ALS is strategic. It is the most common known inherited genetic cause of a fatal disease with no approved therapies, and the same expansion is associated with frontotemporal dementia. A positive early readout would carry weight beyond a single indication, given the company's claim that repeat expansions underlie more than 40 disorders.


The syndicate also matters. A new lead in Hatteras, alongside returning backers Lumira and adMare and new investors including BDC's Life Sciences Venture Fund, gives the company a broader syndicate at the point where development costs rise sharply. Delivery remains the open question the investors themselves flagged, and the single-AAV design is the company's answer to it.


Source


PR Newswire (CNW) — Specific Biologics Announces Oversubscribed US$35 Million Series A Financing to Advance Gene-Editing Therapy for ALS

0 Comments